Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.

about

An overview of new GLP-1 receptor agonists for type 2 diabetes.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.Human β-defensin-2 production from S. cerevisiae using the repressible MET17 promoter.

P2860

Q38639922-464AB5DE-68DF-4C3D-9857-3424352C23BB Q38937735-4F45D344-F77F-4666-93C0-2AED7D680E45 Q41862144-8340A332-4410-44F8-B745-A622E5CF6A92

P2860

Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.

Item

http://www.wikidata.org/entity/Q40745963

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Albiglutide for treating type ...... ynamics and clinical efficacy.

@en

type

Item

label

Albiglutide for treating type ...... ynamics and clinical efficacy.

@en

prefLabel

Albiglutide for treating type ...... ynamics and clinical efficacy.

@en

P1476

Albiglutide for treating type ...... dynamics and clinical efficacy

@en

P2093

Andreas Brønden

http://www.w3.org/2001/XMLSchema#string

Mikkel Christensen

http://www.w3.org/2001/XMLSchema#string

Signe V Naver

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

The Physiology of Glucagon-like Peptide 1

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

P304

1493-1503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2015.1068288

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Filip K Knop

P577

2015-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26166682

http://www.w3.org/2001/XMLSchema#string

Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.

about

P2860

P2860

Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698